within Pharmacolibrary.Drugs.ATC.N;

model N07BC02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 2.3333333333333332e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0024,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009,
    Tlag           = 1200,            
    Vdp             = 0.0025,
    k12             = 0.75,
    k21             = 0.75
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07BC02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Methadone is a synthetic opioid agonist primarily used for the treatment of opioid dependence and chronic pain. It acts on the same opioid receptors as morphine and heroin, but with a longer duration of action. Methadone is approved and widely used today for maintenance therapy in opioid addiction and for pain management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Kreutzwiser, D, &amp; Tawfic, QA (2020). Methadone for Pain Management: A Pharmacotherapeutic Review. <i>CNS drugs</i> 34(8) 827–839. DOI:<a href=&quot;https://doi.org/10.1007/s40263-020-00743-3&quot;>10.1007/s40263-020-00743-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32564328/&quot;>https://pubmed.ncbi.nlm.nih.gov/32564328</a></p></li><li><p>Kokubun, H, et al., &amp; Uezono, Y (2020). Population Pharmacokinetics of Methadone after Oral Administration in Japanese Patients with Cancer-Related Pain. <i>Journal of pain &amp; palliative care pharmacotherapy</i> 34(4) 203–210. DOI:<a href=&quot;https://doi.org/10.1080/15360288.2020.1785070&quot;>10.1080/15360288.2020.1785070</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32870067/&quot;>https://pubmed.ncbi.nlm.nih.gov/32870067</a></p></li><li><p>Niemi, M, et al., &amp; Kivistö, KT (2003). Pharmacokinetic interactions with rifampicin : clinical relevance. <i>Clinical pharmacokinetics</i> 42(9) 819–850. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200342090-00003&quot;>10.2165/00003088-200342090-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12882588/&quot;>https://pubmed.ncbi.nlm.nih.gov/12882588</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07BC02;
